Annals of Oncology 15:161-171, 2004
© 2004 European Society for Medical Oncology
Original Paper |
Dose-dense regimen of temozolomide given every other week in patients with primary central nervous system tumors
Received 22 May 2003; revised 28 July 2003; accepted 12 August 2003Background:
Temozolomide has shown activity and limited toxicity in patients with primary brain tumors at doses of 150–200 mg/m2/day on days 1–5 every 4 weeks. In this study, a new alternative dose-dense regimen of temozolomide was explored in patients with recurrent brain tumors.
Patients and methods:
In this study, we evaluated the safety, dose-limiting toxicity, maximum tolerated dose, recommended dose and activity of temozolomide given on days 1–3 and 14–16 every 28 days (one cycle). The starting daily dose was 200 mg/m2 in a group of at least six patients, with subsequent increments of 50 mg/m2 in groups of at least 12 patients until unacceptable toxicity was reached. Oral ondansetron (8 mg) was given 1 h prior to temozolomide administration. McDonald’s criteria were used to evaluate antitumor activity.
Results:
Seventy patients with brain tumors entered this study. The median number of prior chemotherapy treatments was two (range 1–3). Patients were assigned to one of four groups to receive temozolomide at daily doses of 200 (seven patients), 250 (13 patients), 300 (38 patients) and 350 mg/m2/day (12 patients). The absence of dose-limiting toxicity at cycle 1 led us to establish dose recommendations based on toxicity after repeated cycles. A total of 23, 72, 192 and 83 cycles were given at daily doses of 200, 250, 300 and 350 mg/m2, respectively. Grade 3–4 thrombocytopenia was observed in 0/7, 1/13, 5/38 and 4/12 patients treated at doses of 200, 250, 300 and 350 mg/m2/day, respectively. Grade 3–4 neutropenia was observed in 1/7, 0/13, 3/38 and 4/12 patients treated with 200, 250, 300 and 350 mg/m2/day temozolomide, respectively. At a dose of 350 mg/m2, sustained grade 2–3 thrombocytopenia did not allow treatment to be resumed at day 14 in >40% of patients, and this dose was considered to be the maximum tolerated dose. Thus, a dose of 300 mg/m2/day that was associated with <20% treatment delay due to sustained hematological toxicity was considered as the recommended dose. Objective responses were reported in 13 patients.
Conclusions:
Temozolomide can be given safely using a dose-dense regimen of 300 mg/m2/day for 3 consecutive days every 2 weeks in patients with recurrent brain tumors.
1 Department of Medicine, Institute Gustave-Roussy, Villejuif; 2 Schering Plough, Levallois-Perret; 3 Department of Neurological Surgery, Hôpital Kremlin Bicetre; 4 Department of Neurological Surgery, Hôpital Saint-Anne, Paris, France
Key words: astrocytoma, glioblastoma, high-dose chemotherapy, oligodendroglioma, phases I–II
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  D. P. Cahill, K. K. Levine, R. A. Betensky, P. J. Codd, C. A. Romany, L. B. Reavie, T. T. Batchelor, P. A. Futreal, M. R. Stratton, W. T. Curry, et al. Loss of the Mismatch Repair Protein MSH6 in Human Glioblastomas Is Associated with Tumor Progression during Temozolomide Treatment Clin. Cancer Res., April 1, 2007; 13(7): 2038 - 2045. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. T. Wong, A. A. Brandes, and A. Tosoni Is protracted low-dose temozolomide feasible in glioma patients? Neurology, August 8, 2006; 67(3): 543 - 544. [Full Text] [PDF]
|
|
|
|
|
|
A. Tosoni, G. Cavallo, M. Ermani, L. Scopece, E. Franceschi, C. Ghimenton, M. Gardiman, L. Pasetto, V. Blatt, and A. A. Brandes Is protracted low-dose temozolomide feasible in glioma patients? Neurology, February 14, 2006; 66(3): 427 - 429. [Abstract] [Full Text] [PDF]
|
|